GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Price-to-Owner-Earnings

Contineum Therapeutics (Contineum Therapeutics) Price-to-Owner-Earnings : (As of Jun. 11, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Price-to-Owner-Earnings?

As of today (2024-06-11), Contineum Therapeutics's share price is $18.00. Contineum Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Contineum Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


CTNM's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.445
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-11), Contineum Therapeutics's share price is $18.00. Contineum Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.60. Therefore, Contineum Therapeutics's PE Ratio for today is At Loss.

As of today (2024-06-11), Contineum Therapeutics's share price is $18.00. Contineum Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.59. Therefore, Contineum Therapeutics's PE Ratio without NRI for today is At Loss.


Contineum Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Contineum Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Price-to-Owner-Earnings Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - -

Contineum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial - - - - -

Competitive Comparison of Contineum Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Contineum Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Contineum Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Contineum Therapeutics's Price-to-Owner-Earnings falls into.



Contineum Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Contineum Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=18.00/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Contineum Therapeutics  (NAS:CTNM) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Contineum Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Contineum Therapeutics (Contineum Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus